SaNOtize Research and Development Corp.

10:45 AM - 11:00 AM (EDT), Wednesday, June 7, 2023 ・ Session Room 104A
A clinical stage, specialty pharmaceutical company with a disruptive anti-infective platform technology. Our pioneered a first-in-class, nitric oxide-releasing solution (NORS) aims to improve the quality of life for hundreds of millions of people suffering from a constellation of topical infections. SaNOtize’s patented innovation (rich IP portfolio) unleashes the therapeutic benefits of nitric oxide by using a liquid to create and deliver a safe, dose controlled amount of NO gas to the site of infection.
NO is a gaseous molecule that is a non-antibiotic, non-specific, antimicrobial that kills viruses, fungi and bacteria. NO also is a nonsteroidal, anti-inflammatory and increases blood flow to the site of application. Inhaled NO has been safely used for 20+ years on babies.
Initial focus is on respiratory infections such as influenza / COVID, and chronic sinusitis, as well as on topical infections such as
onychomycosis , warts and diabetic foot ulcer.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
NORS - nasal spray
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
SaNOtize Research and Development Corp.